Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 30;15(1):109–114. doi: 10.3892/ol.2017.7293

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — The effect of combined SFN and gefitinib therapy on PC9GT cells was determined using a cell proliferation assay and western blotting. (A) Combined treatment markedly decreased PC9GT cell proliferation, when compared with SFN or gefitinib monotherapy, at 48 and 72 h (*P<0.05, compared with SFN, gefitinib and the control). (B) SFN combined with gefitinib markedly inhibited the expression of SHH, SMO, GLI1, CD133 and CD44 in PC9GT cells, as compared with SFN or gefitinib administered alone. SFN, sulforaphane; PC9GT, gefitinib-tolerant PC9 cells; EGFR, epidermal growth factor receptor; SHH, sonic hedgehog; SMO, Smoothened; GLI1, zinc finger protein GLI1.